Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue
Conditions
Interventions
Intervention1: Superbioavailable itraconazole: Superbioavailable itraconazole 65mg twice a day for 6 weeks
Control Intervention1: Conventional Itraconazole: Conventional Itraconazole 100 mg twice a da
Sponsors
Dr NagiReddy Apoorva Reddy
Eligibility
Inclusion criteria
Inclusion criteria: 1.Males and females greater than 18yrs of age who are clinically proven cases of Tinea Cruris,Tinea Corporis along with proven positive KOH mount 2.Patient with chronic dermatophytosis without any antifungal therapy for at least 3 weeks prior to study
Exclusion criteria
Exclusion criteria: 1.Age greater than 60 2.Patients with Tinea involving the Non Glabrous Area (Tinea capitis,Tinea unguium,Tinea Mannum,Tinea Pedis. 3.Patients with any significant medical illness such as Diabetes,Cardiac,Liver and Chronic Kidney diseases,Immunocompromised conditions 4.Pregnant and lactating females 5.Children 6.Patients who have documented intolerance ,allergy or hypersensitivity to Itraconazole
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The Primary outcome of the study will be the assessment of Clinical Response in terms of reduction in TSS score,BSA score & Percentage of Patients achieving the Complete cure( Clinical & Mycological cure ) at the end of treatment of 6 weeks period in both the groups.Timepoint: Baseline,6weeks and 10weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| ? The secondary outcome of this study will be evaluation of reasons of relapse & clinical failure. Timepoint: 10 weeks | — |
Countries
India
Contacts
Public ContactDrNagireddy Apoorva Reddy
Apollo Institute of Medical Sciences and Research,
Outcome results
None listed